William Rice: Okay. I’ll take on the next part. So regarding the MDS patients, as Dr. Bear said, there is a need. There’s also a great deal of larger pharma, larger biotech companies who are interested in seeing data in those patients because it ticket represent a large commercial opportunity. Regarding the resource allocation, currently, we’re forming the test in doublet study with patients. As I said, those patients have been accruing very rapidly, and we expect to be able to tidy up that trial probably 1.5 to 2 orders, two quarters earlier than expected. So in terms of our next top priorities for how we’re going to allocate the resources, the next one is — the next top priority is that triplet the bin, the Tustin HMA triplet.
It’s the pilot study in, say, 20 to 40 patients. There’s tremendous interest in driving this drug to the frontline newly diagnosed patients, and we’d like to get data there as quickly as possible. The next priority then would be the MDS MML patients. Again, tremendous interest from a variety of additional resources outside of our company that are interested in that patient population. Beyond that, then we would look to the registrational trials that can then start. The first would be in the doublet patients so that would be tossed in the relapsed refractory patients who have failed Venetoclax previously and then after that would be the triplet, the registration trial for the triplet and frontline newly diagnosed patients. So did that Anish, thanks for the question.
Did that answer it?
Unidentified Analyst: Yes. Great. Thanks so much for the color.
William Rice: Okay. Thanks for being here today.
Operator: [Operator Instructions] I’m currently showing no further questions. I will now turn the call back to Dr. Rice for closing remarks.
William Rice: Okay. Thank you so much. I also want to thank everyone for joining us this afternoon. As you can tell, we’re really excited about the growing body of safety and efficacy data on Tuspetinib and the Tuspetinib-Venetoclax combination and these very difficult to treat patient populations of AML. We believe Tuspetinib could improve upon the standard of care for AML patients that are currently in perfectly served by the current therapies. As always, we thank our patients, investigators and employees for their important role in this effort. Our clinical team has been key in ramping up the enrollment in the ACTIVATE trial and collecting data for our latest data cut, and I’ll continue to recognize them for their execution. We appreciate our shareholders and analysts who continue to support us, and we look forward to keeping you updated on our progress. I want to thank all of you, and have a wonderful even. Take care. Bye-bye.
Operator: Thank you, ladies and gentlemen. That concludes today’s conference. You may all disconnect, and have a wonderful day.
